10-Q: Corbus Pharma Q3 2025: R&D Soars, New Capital Secured

Corbus Pharmaceuticals reports increased R&D expenses and net losses in Q3 2025, while securing significant capital through recent offerings to fund its clinical pipeline.

Summary

• Net loss for the three months ended September 30, 2025, was $23.3 million, compared to $13.8 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $58.0 million, compared to $30.7 million for the same period in 2024.
• Research and development (R&D) expenses increased by 93% to $20.9 million for Q3 2025 and by 121% to $51.7 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• General and administrative (G&A) expenses decreased by 24% to $3.6 million for Q3 2025 and by 8% to $11.7 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
• Cash, cash equivalents, and investments totaled approximately $104.0 million as of September 30, 2025.
• Subsequent to the quarter-end, the company raised approximately $70.2 million in net proceeds from a public offering completed on November 3, 2025, and an additional $3.6 million in net proceeds from an Open Market Sale Agreement from October 1, 2025, through the filing date.
• The company expects its current capital, combined with the recent capital raises, to be sufficient to meet operating and capital requirements for at least twelve months from the issuance of this Quarterly Report on Form 10-Q.
• Clinical progress includes the completion of the dose escalation phase for CRB-701 (oncology ADC), initiation of a PD-1 combination arm in June 2025, ongoing Phase 1 dose escalation for CRB-601 (oncology antibody), and ongoing Phase 1 SAD/MAD for CRB-913 (obesity) with no treatment-related neuropsychiatric events observed in the SAD portion.

Sentiment

Score: 4

Explanation: While the company made clinical progress and secured significant funding post-quarter, the substantial increase in net losses and R&D expenses, coupled with a high accumulated deficit, reflects a challenging financial position and continued reliance on capital raises. The positive clinical updates are offset by the increased cash burn.

Positives

• Successfully raised approximately $70.2 million in net proceeds from a public offering and $3.6 million from an Open Market Sale Agreement post-quarter end, significantly extending liquidity.
• CRB-701 (oncology ADC) completed its dose escalation phase, initiated a PD-1 combination arm in June 2025, and presented dose optimization data at ESMO in October 2025, indicating strong clinical advancement.
• CRB-601 (oncology antibody) Phase 1 dose escalation is ongoing, with the first participant dosed in December 2024 and regulatory approval received in the U.K. in January 2025.
• CRB-913 (obesity) Phase 1 SAD portion showed an absence of treatment-related neuropsychiatric events, addressing a key safety concern for CB1 inverse agonists.
• General and administrative expenses decreased for both the three and nine months ended September 30, 2025, compared to the prior year periods.
• No interest expense on debt was incurred in 2025, as the K2HV loan was fully repaid in August 2024.

Negatives

• Net loss significantly increased to $23.3 million for Q3 2025 (from $13.8 million in Q3 2024) and to $58.0 million for the nine months ended September 30, 2025 (from $30.7 million in 9M 2024).
• Research and development expenses more than doubled for the nine-month period, reaching $51.7 million, indicating a substantial increase in cash burn for clinical programs.
• Accumulated deficit reached approximately $534.9 million as of September 30, 2025, reflecting a history of operating losses.
• The company continues to be dependent on raising substantial additional capital to fund its operations and ongoing clinical trials.
• Cash used in operating activities increased to $48.6 million for the nine months ended September 30, 2025, from $30.9 million in the prior year period.

Risks

• History of operating losses and anticipation of continued operating losses for the foreseeable future.
• Significant current and future capital requirements and uncertainty regarding the ability to satisfy capital needs.
• Ability to complete required clinical trials and obtain approval from the FDA or other regulatory agents in different jurisdictions.
• Ability to internally develop new product candidates, intellectual property, and other product candidates that may be acquired and/or licensed.
• Ability to maintain or protect the validity of patents and other intellectual property.
• Ability to retain key executive members.
• Interpretations of current laws and the passage of future laws.
• Acceptance of the business model by investors.
• Accuracy of estimates regarding expenses and capital requirements.
• Ability to adequately support growth.
• Adverse global conditions, including economic uncertainty, pandemics, geopolitical instability, increased trade tariffs, and supply chain weaknesses, may negatively impact financial results.
• Tariffs, trade restrictions, or sanctions could increase global clinical trial costs, material costs, affect commercialization, or create adverse tax consequences.

Future Outlook

The company expects its cash, cash equivalents, and investments of approximately $104.0 million at September 30, 2025, combined with $73.8 million from recent stock sales, to be sufficient to meet operating and capital requirements for at least twelve months from the issuance of this 10-Q. Significant additional capital will be needed to fund ongoing clinical trials for CRB-701, CRB-601, and CRB-913. The company anticipates commencing a registrational study for CRB-701 by mid-2026. CRB-913 SAD/MAD data is expected in the fourth quarter of 2025, along with the initiation of a Phase 1b dose-range finding study in obese non-diabetic individuals.

Management Comments

• We are a clinical-stage oncology and obesity company and are committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.
• We expect to continue to incur significant expenses for the foreseeable future.
• We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of our product candidates.
• We will continue to incur significant operating losses as we move into the clinical phase and, accordingly, we will need additional financing to support our continuing operations.
• We will seek to fund our operations through public or private equity, debt financings or other sources, which may include government grants and collaborations with third parties.
• Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.
• We will need to generate significant revenues to achieve profitability, and we may never do so.

Industry Context

Corbus Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncology (ADCs, anti-integrin antibodies) and obesity (CB1 receptor inverse agonists). The development of ADCs like CRB-701 is a growing area in oncology, aiming for targeted drug delivery with reduced systemic toxicity. Anti-integrin antibodies like CRB-601 represent another approach to modulate the tumor microenvironment. The obesity drug market is also significant, with a focus on improved safety profiles for weight loss medications, especially given past issues with CB1 agonists. The company's strategy involves advancing multiple candidates through clinical trials, a common approach for biotech firms to diversify risk and increase chances of success.

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings, but may become a party to various legal proceedings arising in the ordinary course of business.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity offerings, but also potential for long-term value creation if pipeline candidates succeed. There is an ongoing risk of further losses.
• Employees benefit from continued employment and potential for stock-based compensation, but are under pressure to deliver on clinical milestones.
• Future patients could benefit from new treatments in oncology and obesity if product candidates are successfully developed and approved.
• Creditors see reduced immediate risk due to the recent capital raise, but ongoing operational losses indicate continued financial risk.
• Suppliers and partners will continue to be engaged for clinical trials and drug supply, with milestone payments tied to development progress.

Next Steps

• Engage and consult with the FDA regarding the design of a registrational study for CRB-701.
• Anticipate commencing a registrational study for CRB-701 by mid-2026.
• Continue dose escalation for CRB-601.
• Report SAD/MAD data for CRB-913 in the fourth quarter of 2025.
• Initiate a Phase 1b dose-range finding study for CRB-913 in obese non-diabetic individuals in the fourth quarter of 2025.
• Raise significant additional capital to fund ongoing clinical trials.

Key Dates

Recommendation

The company is making clinical progress across its pipeline, particularly with CRB-701 and CRB-913 showing promising early signs (completion of dose escalation, no neuropsychiatric events). The recent capital raise significantly bolsters liquidity, providing a runway for at least 12 months. However, the substantial increase in net losses and R&D expenses highlights the high-risk, high-reward nature of clinical-stage biotech. While the funding provides stability, the path to profitability remains long and uncertain, with significant future capital needs. Investors should hold to monitor further clinical data and progress towards registrational studies, as these milestones will be critical for future valuation.

Keywords

Corbus Pharmaceuticals, CRBP, oncology, obesity, antibody drug conjugate, ADC, Nectin-4, CRB-701, anti-integrin, CRB-601, cannabinoid type-1 receptor inverse agonist, CB1, CRB-913, clinical trials, Phase 1/2, Phase 1, drug development, biotechnology, pharmaceuticals, SEC filing, 10-Q, capital raise, public offering, Jefferies, Keytruda, pembrolizumab, ESMO, SITC